Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating increased interest from rheumatologists despite some skepticism on efficacy ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...